Public Health Trace

Get Alerts

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to October 2026.

37,211

Total recall recordsAll FDA and USDA recalls in Public Health Trace

9,841

Class I recallsReasonable probability of serious health consequences

24,366

Class II recallsTemporary or medically reversible health consequences

2,892

Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls

Most common hazardLack of Assurance of Sterility 2,073 recalls

Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/frutas-y-hortalizas-del-sur-sa-expands-recalls-include-additional-lots-great-value-frozen-organicPublished October 2, 2026

Most affected stateHawaii 200 recalls mention this state

State: ND ×
Clear all

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters

Timeline Classification Table

Metric

Time range

Group by

View

Recalls announced by month (Year to date)

Download CSV

Source: FDA and USDA public dataLast updated October 3, 2026 ET

Summary (Year to date)

1,714 recalls have been announced year to date.
Sep 2026 was 3% higher than the previous complete period (Aug 2026: 182).
The highest complete period was Jun 2026 (297).
Oct 2026 is incomplete and not included in the figures above.

Complete data
Incomplete

Recalls by class

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

FDA Recall Ongoing Historical recordClass II

Betamethasone Phosphate/Acetate 6 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Betamethasone Sodium Phosphate 12 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Beta Alanine 100 mg/ml / l-carnosine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Atropine Sulfate 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Aminophylline 2.5% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Aminocaproic Acid 0.5mg/ml Injection,compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Aminocaproic Acid 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Altrenogest 50 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Alprostadil 2000 mcg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Adenosine-Mono-Phosphate Injection, 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Acepromazine 25 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Camila (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0715-58

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dose Vial, Rx only, APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-184-11

by Fresenius Kabi USA, LLC

Reason: Failed Impurities/Degradation Specification
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Gentamicin Sulfate Injection USP 80 mg/2 mL(40 mg/mL as Gentamicin), 2 mL Single-dose Fliptop Vial, (NDC 0409-1207-13), Rx only, Manufactured by Hospira, Inc, Lake Forest, IL 60046 USA.

by Hospira Inc.

Reason: Presence of Particulate Matter: visible particles were identified floating in the primary container.
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial, Rx only, labeled as a) Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-970-02; and b) Manufactured in the USA for Nexus Pharmaceuticals Inc., Vernon Hills, IL 60061, NDC 14789-300-02

by Fresenius Kabi USA, LLC

Reason: Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Lessina(R) (Levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg, 28 day regimen, Rx only, Barr Laboratories Inc., Pomona, NY --- NDC 0555-9014-67

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published: July 17, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/5.0 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA 1910, NDC 0046-0975-11

by Pfizer Inc.

Reason: Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the specification for conjugated estrogens dissolution.
Published: July 10, 2013
Distribution: Nationwide

View recall →

Data last updated: October 3, 2026 ET

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.